by ASTCT Talks
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD,...
by Blood Advances
CD70 may be a promising target for preventing acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) or treating it once it has developed,...
by Dr. Corey Cutler, MD, MPH
In the September President's Message, Dr. Corey Cutler, MD, MPH, shares the importance of Sickle Cell Awareness Month and the progress made in treating the disease, particularly through gene...
by Alex Kadhim
In a multicenter study, researchers have initiated a first-in-human phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating...
by Blood Advances
For patients undergoing hematopoietic cell transplantation (HCT) from a 10/10 HLA-matched unrelated donor, scientists agree that the age of the donor matters more than T-cell epitope DP-matching.
The 2024 EPBMTC offers a robust scientific program that includes a wide range of educational sessions focused on the current practices and challenges of Pediatric Hematopoietic Stem Cell...